Currently, there are three treatments currently available for the treatment of pulmonary hypertension, which all work to slow the rate of loss of lung function. However, the treatment landscape is likely to evolve with the positive TETON trials demonstrating that inhaled treprostinil has independent antifibrotic properties. Expert Steven Nathan, MD, Inova, looks ahead to the future of disease-modifying therapies and what these advances mean for patients and pulmonologists, with host Ugo Ezema, MD, Tulane.